



Resource impact template

Resource impact

Published: 8 May 2024

Last updated: 8 May 2024

www.nice.org.uk

NICE has produced a [resource impact template](#) that incorporates the following technology appraisal guidance for COVID-19:

- Remdesivir and tixgevimab plus cilgavimab for treating COVID-19 (2024) NICE technology appraisal guidance 971
- Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (2023) NICE technology appraisal guidance 878